Article

Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene

Department of Medicine, Washington University, St Louis, Missouri, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 30.39). 04/2011; 305(15):1577-84. DOI: 10.1001/jama.2011.497
Source: PubMed

ABSTRACT Whole-genome sequencing is becoming increasingly available for research purposes, but it has not yet been routinely used for clinical diagnosis.
To determine whether whole-genome sequencing can identify cryptic, actionable mutations in a clinically relevant time frame. DESIGN, SETTING, AND PATIENT: We were referred a difficult diagnostic case of acute promyelocytic leukemia with no pathogenic X-RARA fusion identified by routine metaphase cytogenetics or interphase fluorescence in situ hybridization (FISH). The case patient was enrolled in an institutional review board-approved protocol, with consent specifically tailored to the implications of whole-genome sequencing. The protocol uses a "movable firewall" that maintains patient anonymity within the entire research team but allows the research team to communicate medically relevant information to the treating physician.
Clinical relevance of whole-genome sequencing and time to communicate validated results to the treating physician.
Massively parallel paired-end sequencing allowed identification of a cytogenetically cryptic event: a 77-kilobase segment from chromosome 15 was inserted en bloc into the second intron of the RARA gene on chromosome 17, resulting in a classic bcr3 PML-RARA fusion gene. Reverse transcription polymerase chain reaction sequencing subsequently validated the expression of the fusion transcript. Novel FISH probes identified 2 additional cases of t(15;17)-negative acute promyelocytic leukemia that had cytogenetically invisible insertions. Whole-genome sequencing and validation were completed in 7 weeks and changed the treatment plan for the patient.
Whole-genome sequencing can identify cytogenetically invisible oncogenes in a clinically relevant time frame.

Download full-text

Full-text

Available from: Shashikant Kulkarni, Aug 27, 2015
1 Follower
 · 
265 Views
  • Source
    • "As a result, ES/WGS have quickly been transitioned from use as a research tool to use in clinical service labs as an alternative to targeted genetic testing. Several widely publicized examples in which these tools have been used to facilitate a clinical diagnosis have further engendered enthusiasm for adopting ES/ WGS into clinical practice [Bainbridge et al., 2011; Welch et al., 2011; Worthey et al., 2011]. We are similarly enthused, but such swift translation of ES/WGS into clinical settings raises important questions such as: (1) under what circumstances is ES/ WGS likely to be of greatest clinical benefit, (2) how can informed consent for ES/WGS effectively be obtained, (3) what are reasonable options to offer for sharing individual ES/WGS (iES/WGS) results, (4) how should iES/WGS results be managed for providers and families, and (5) how can providers' and families' expectations about risk profiling using ES/WGS be managed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Exome and whole genome sequencing (ES/WGS) offer potential advantages over traditional approaches to diagnostic genetic testing. Consequently, use of ES/WGS in clinical settings is rapidly becoming commonplace. Yet there are myriad moral, ethical, and perhaps legal implications attached to the use of ES and health care professionals and institutions will need to consider these implications in the context of the varied practices and policies of ES service providers. We developed "core elements" of content and procedures for informed consent, data sharing, and results management and a quantitative scale to assess the extent to which research protocols met the standards established by these core elements. We then used these tools to evaluate the practices and policies of each of the 6 U.S. CLIA-certified labs offering clinical ES. Approaches toward informed consent, data sharing, and results return vary widely among ES providers as do the overall potential merits and disadvantages of each, and more importantly, the balance between the two. © 2013 Wiley Periodicals, Inc.
    American Journal of Medical Genetics Part A 05/2013; 161(5):935-50. DOI:10.1002/ajmg.a.35942 · 2.05 Impact Factor
  • Source
    • "This discovery permitted the patient to be treated for APL rather than having a stem cell transplant, thereby avoiding a high cost procedure with high morbidity and mortality risk. So far the patient's outcome is promising [Welch et al., 2011]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The fourth Personal Genomes meeting was held at Cold Spring Harbor Laboratory, New York, from 30 September to 2 October and provided an exciting collection of science built on recent significant milestones in individual human genome sequencing, from the first personal genomes to thousands of human genomes sequenced. As ultra-high throughput sequencing platforms enable the production of more and more individual genomes, a growing number of scientists, physicians, and clinical geneticists are actively exploring the promise and the implications of these new data. Personal Genomes brought many of these pioneers together with nearly 200 scientists, physicians, ethicists, and others to discuss the progress and opportunities around the sequencing and medical interpretation of individual genome sequences.
    Human Mutation 06/2012; 33(6):1016-9. DOI:10.1002/humu.22024 · 5.05 Impact Factor
  • Source
    • "Deciphering biologically relevant DNA mutations Whole-genome data allow for the interpretation of sequence variants in the context of a tumor's entire genomic landscape. Interpretation of omics data for any malignancy, in a biologically relevant context, is paramount to the clinical translation of this information (Jones et al. 2010; Lunshof et al. 2010; Link et al. 2011; Pasche and Absher 2011; Welch et al. 2011). The most biologically relevant alterations are ''drivers'' of tumorigenesis that underlie particular tumor features or behaviors, such as treatment response, and generally represent ideal candidates for therapeutic intervention . "
    [Show abstract] [Hide abstract]
    ABSTRACT: The genomics era has yielded great advances in the understanding of cancer biology. At the same time, the immense complexity of the cancer genome has been revealed, as well as a striking heterogeneity at the whole-genome (or omics) level that exists between even histologically similar tumors. The vast accrual and public availability of multi-omics databases with associated clinical annotation including tumor histology, patient response, and outcome are a rich resource that has the potential to lead to rapid translation of high-throughput omics to improved overall survival. We focus on the unique advantages of a multidimensional approach to genomic analysis in this new high-throughput omics age and discuss the implications of the changing cancer demographic to translational omics research.
    Genome Research 02/2012; 22(2):188-95. DOI:10.1101/gr.124354.111 · 13.85 Impact Factor
Show more